Monthly Archives: February 2020

AposTherapy and Ahava Medical & Rehabilitation Center Bring a Non-Surgical, Drug-Free Solution to Knee and Lower Back Pain Sufferers in Brooklyn -…

Posted: February 27, 2020 at 1:42 am

Brooklyn, N.Y., Feb. 26, 2020 (GLOBE NEWSWIRE) -- AposTherapy and Ahava Medical & Rehabilitation Center have partnered to bring Brooklyn residents suffering from knee and lower back pain a non-invasive, drug-free alternative to surgery. The AposTherapy program is now offered at Ahava Medical & Rehabilitation Brooklyn (Williamsburg), located at 16 Sumner Place, Brooklyn, NY 11206.

AposTherapy works on biomechanical and neuromuscular levels, combining a treatment program and a foot-worn, patented medical device that patients wear for approximately an hour a day while going about their regular routine. The treatment addresses the underlying causes of the pain by reducing load on the painful areas of the knee and re-training muscles. Over time, AposTherapy corrects abnormal walking patterns even when not actively wearing the device.

Clinical studies have shown significant reduction in pain and improvement in function and quality of life, as well as significant reduction in the use of pain medications like opioids.

"There is a growing need for a non-surgical and opioid-free knee and lower back pain treatment," said Dr. Cliff Bleustein, President and CEO of AposTherapy. "Ahava Medical & Rehabilitation Center is well known for their innovative approach to patient care, and partnering with AposTherapy will allow them to bring more personalized care to their community. The treatment is effective and convenient, giving the patient the power and freedom that comes with restored mobility and a healthier life."

About AposTherapy

AposTherapy is an innovative, FDA cleared treatment for knee osteoarthritis and qualifies as a wellness device for use with other musculoskeletal conditions such as lower back pain. AposTherapy works on biomechanical and neuromuscular levels, combining a foot-worn patented medical device with a treatment program. The treatment addresses the underlying causes of pain by shifting pressure away from painful areas and providing a long-lasting neuromuscular effect by re-educating muscles to a healthier walking pattern, even when not wearing the device.

AposTherapy can be an alternative to surgery for some patients who cannot or would prefer not to undergo knee surgery.

By improving body mechanics and muscular coordination, AposTherapy has shown in extensive clinical research that patients can achieve significant pain relief as well as an improvement to their daily function and quality of life.

For more information, visit AposTherapy.com.

Connect with AposTherapy on Facebook, Twitter, YouTube, and LinkedIn.

About Ahava Medical & Rehabilitation Center

Ahava Medical & Rehabilitation was established in 1998 with the goal of providing a community-based medical and rehabilitation center for the healthcare needs of the community. This full service multi-specialty group employs a staff of over 120 health care professionals and serves patients at four locations throughout Brooklyn and surrounding areas of New York City.

Ahava helps patients by utilizing the latest medical techniques and technology in the areas of physical therapy, occupational therapy, aquatic therapy and speech & language therapy. They also provide urgent care as well as comprehensive internal medicine, pediatric, OB/GYN, family medicine and psychiatric care.

For more information, visit AhavaMedical.com.

###

See the rest here:

AposTherapy and Ahava Medical & Rehabilitation Center Bring a Non-Surgical, Drug-Free Solution to Knee and Lower Back Pain Sufferers in Brooklyn -...

Posted in Alternative Medicine | Comments Off on AposTherapy and Ahava Medical & Rehabilitation Center Bring a Non-Surgical, Drug-Free Solution to Knee and Lower Back Pain Sufferers in Brooklyn -…

FACE TO FACE: Our own Dr King ready to shake the political throne – Bahamas Tribune

Posted: at 1:42 am

By FELICITY DARVILLE

It takes a lot of guts to start your own political movement. Many people have complaints about the system of government. People call in to the talk shows, they make their social media posts and they speak out at town meetings. Some people will complain to whoever will listen. But how often does someone take a bold step and actually form their own group and seek the support of the Bahamian people at the election polls? Very few have and hats off to those who have put themselves on the line in this way.

The Bahamian society can be harsh, judgmental and difficult to persuade to make a change, as much as people may complain. Dr Kevin King knows this. Yet in 2018, he introduced the Kingdom Government Movement (KGM). He refers to it as The Voice of Change and on Friday, March 20, he will introduce his first set of candidates. Eventually, the KGM will present a full slate of candidates who will contest every seat in the country. KGM sets out to become the first organisation to successfully upset the two-party trend that has defined the political culture of the country and come up with a win.

The KGM has a vision to accomplish certain things if elected, within the first 30 days in office. They include: reducing VAT from 12 percent, back to 7.5 percent; calling for a referendum to replace the Westminster system with a parliamentary republic system; calling for a referendum to replace the monarchy, Privy Council and Governor General as head of state; introducing a new Bahamian land ownership policy; implementing new, affordable housing systems; implementing new manufacturing, industries and renewable energy platforms.

So, what does it take to make such a bold move? Kevin says it was God himself who gave him the instruction to create the KGM with a philosophy to uphold the preamble of the Constitution of the Bahamas, which recognises the Bahamas as a Christian Nation under the supremacy of God.

Its not the first time he has received a Divine message. He first started hearing the voice of God speak to him at the tender age of eight and ever since, he has been listening to the voice that has allowed his life to unfold in a miraculous way. He was born in Nassau to Olive Louise King, nee Stubbs and he is one of eight siblings. His ancestors include Gabriel Nairn and Ophelia Ramsey of the Cove, Cat Island, and he is the grandson of Alfred King of Knowles, Cat Island and Maude King of Adelaide Village. He spent most of his childhood in Adelaide. Even to this day, Adelaide is still a quaint, sleepy village with beautiful natural habitats around. He also spent some of his formative years in Freeport, Grand Bahama.

I used to go out to the pine yard by myself and sit down, Kevin recalls of his childhood.

I was in tune with nature. Birds and insects would come around. Sometimes, I would be there hours on end. My childhood nickname was Gubby. My brothers and sisters would say, Gubby gone into the wilderness. Once I was finished my chores, thats where I would go, and God would speak to me.

When Kevin was in primary school, he would find moments to be alone to pray. When kids would go out at playtime, he would stay in class, and close the windows so that he could commune with God alone. He cherished opportunities to have conversations with God.

That continued all through my life, he shared. I was a part of every Christian movement that I could be growing up. As an adult, I was ordained as a prophet and a pastor. I have travelled all over the world ministering. It consumes me.

As a minister, Kevin made history when Messianic Jewish Ministry International, Hebrew Torah Institute and World Prayer Towers appointed him as the director of a new World Prayer Tower established in The Bahamas. It happened during a special dedication service at Bethany Assemblies of God where he was anointed with oil by Rabbi Daniel Jeshurun Vargas, founder and executive director.

Kevin grew up in the Anglican and Catholic churches, and came under the tutelage of Father Caldon in Adelaide, Bishop Michael Eldon, Father Brennan, Father Pestaina, and Father Richardson. Later on he attended the Assemblies of God, guided by Pastor Ferguson, Gilbert Roberts, Ernie Deloach, Bishop Jonathan Carey, Bishop Sobig Kemp, Pastor Roberts, and Bishop Ross Davis. He attended many Bible schools including West Indies College in Mandeville, Jamaica. He also sang in many gospel groups. To date, he has studied numerous religions all around the world.

In the 1980s his studies also took him to the US and there, he worked in sales and moved up the ranks to management. He also worked in the restaurant business and even served as a bodyguard at one point. Kevin appeared in television commercials and he also frequented WEDR, where he learned radio announcing from Leo, Jimmy G, and Super Jerry Rushing. He returned home and worked in sales for ZNS radio and television in Grand Bahama. For a while, he pursued his interest in law and studied with brilliant attorneys like Stephen Wilchcombe, Moses A Hall, Fayne Thompson and Kenneth Lewis.

By the 1990s, Kevin decided to change his profession. He took up medical studies at Concord Career Institute in Miramar, Florida. He was at the top of his class and was doing well when he said the voice of God spoke to him. He was instructed to study natural medicine and provide the people in his home country with this service. He took a big leap of faith and answered the call. He studied natural medicine in Sri Lanka, The Philippines, Hong Kong, Canada, Ecuador, New Mexico, India, Australia, and St. Kitts and Nevis. He has been a practicing physician for nearly three decades and is considered the pioneer of natural medicine in The Bahamas. He has had clinics in Freeport, Abaco and Nassau simultaneously.

Kevin has been knighted by St Johns of Jerusalem Knights of Malta for his success in Alternative Medicine. He was also knighted by The Orthodox Order of Saint John under Prince Michael of Russia for his worldwide humanitarian services. In 2004, he was commissioned by the college of Bishops to the nations.

In the same year, Kevin became an International Diplomat and was presented to former Prime Minister Perry Christie by His Excellency Charles Henry McWilliams, and his credentials were presented to then Minister of Foreign Affairs Fred Mitchell. He belongs to many world organisations in health and science and he has lectured to thousands throughout North America, the Caribbean, Europe and Asia.

Kevin was elected as the Chairman of the World Organization of Natural Medicine at a world congress in Quito, Ecuador. He has met with world leaders and Heads of State of many countries around the world, both on diplomatic missions and advancing the cause of Alternative and Natural Medicines.

His latest calling, the KGM, he seeks to enlighten the people of The Bahamas on its philosophies of governance; in that it is NOT a movement of politics with all the nefarious nuances inherent in the party affiliations that is the basis of the Westminster system.

Kingdom Government is a righteous movement that has a purpose of purity to enact real and lasting change for the benefit of the people of the Commonwealth of The Bahamas, at a time when it is necessary and needed the most, he said.

It is not a political party but rather a Paradigm of Progress. We accept this mantle of responsibility in abject humility with an edict of Divine service to the people of this country.

On April 6, 2018, Kevin made his inaugural speech. By October of the same year, he officially launched KGM in New Providence and in Grand Bahama. Samuel Johnson serves as the chairman and Calvin Greene is the national campaign manager. For more information on the Solutions Campaign which will release its candidates this March, visit kingdomgovernmentmovement.org or contact Dr Kevin King at sirkevinking@live.com, or call 810-2694 or 434-2831.

Read the original:

FACE TO FACE: Our own Dr King ready to shake the political throne - Bahamas Tribune

Posted in Alternative Medicine | Comments Off on FACE TO FACE: Our own Dr King ready to shake the political throne – Bahamas Tribune

5 things to know about Miss Anthropocene by Grimes – Vancouver Sun

Posted: at 1:41 am

Grimes. Promo shot for Miss Anthropocene release. 2020 [PNG Merlin Archive]PNG

Grimes | Grimes Creative Corporation/Crystal Math Music

In only a decade, Grimes (a.k.a. Vancouver-born and raised Claire Boucher) has gone from the eerie DYI of 2010s Halifaxa to 2012s confident and expansive critically acclaimed Visions right up to the wildly ambitious and successful sounds of 2015s Art Angels.

Now Miss Anthropocene arrives at a time when Grimes is as much a global brand for her romantic affiliation with Elon Musk and shrewd manipulation of social media platforms as for her music.

Her fifth album is either a concept album about anthropomorphizing climate change into an evil entity, or another delightfully damming confusion of sounds and statements from an artist who is putting out her final earth album this year. This may very well be because she is fed up with all the attention being paid to her amorous adventures rather than her adventurous art.

Spoiler alert: Repeated listenings wont divulge any grand statements about impending global chaos, save for the advice to gleefully fk the world.

However the 11 tracks (or 15 on the superior deluxe edition of the album) are philosophically assembled, Miss Anthropocene lands as one of the first big releases of this decade and certainly one of 2020s most-anticipated records. Here are five things to know about it:

1. So Heavy I Fell Through the Earth. A booming bass line haunts the back of the mix while leaden drums pound out echoing patterns until a vocal bursts forth to lets us all know what Enya huffing helium would sound like. The layers keep on stacking onto the six-minute song, until the lightest thing about it is Grimes repeating the tunes title. The sudden 360 turnaround at the 4:30 mark is quite brilliant, as she apparently falls clean through the planet and its gravity to float in some ambient expanse.

2. Violence (with i_o). This uptempo electro banger is one of the most straightforward songs on the record. But with lyrics such as You wanna make me bad, make me bad/(And I like it like that, and I like it like that), it turns the coquettish pop cluttering up the radio into something far darker and disturbing. Fans will be reading into the juxtaposing of violence, pain, partying and more as some kind of commentary on her relationship. Or Grimes is just eviscerating everyones expectations in public. The video is well worth a peek.

3. New Gods.Even someone used to making sense of the words on extreme black metal recordings could have trouble translating what Grimes is actually saying. Her voice is so often mutated past the point of comprehension, or pinging around the vast echoing background as it does in this song, that you are hard-pressed to pry any kind of meaning out of the music. Which works for a project that is meant to be both ethereal and personal. The mood is as, or more, important than the meaning.

4. Youll miss me when Im not around. From not-fully-realized drum and bass tracks (4M) to the weirdly Taylor Swift-ish acoustic strumming in Delete Forever, the album mixes somewhat experimental approaches with mainstream songcraft. Nowhere is this more realized than in the full-on dance-rock of this hooky track. The heavy guitars coupled with the blasts of mega-manipulated vocal harmonies make this a likely single.

5. We Appreciate Power. Available on the deluxe version of the album, this earlier collaboration with Hana came complete with press statements that it was influenced by everything from pro-A.I. pop bands to ideas of transhumanist desire. OK computer. What is clear is that the songs title is an accurate reflection of the artists being. Its the kind of hard industrial rock track you might expect from Nine Inch Nails, but with a goofball spoken-word bit that could rival Madonnas bad rapping in Vogue. In other words, its more fun than scary. The other remixes on the deluxe edition are of varying quality, with the Algorithm mix of IDORU particularly good.

Myopia | Universal Music Canada

At some point, Obels classical orientation is going to have to take shape in an opera. The voice arrangements paired against the orchestrations in Cameras Rolling sound ready-made to be the opening song to some noir-esque stage play as much as any album track. And that is only the beginning of this lush chamber-pop recordings highlights. Obels music has become even more sparse and flowing with silence used to add emotional impact to every note. Check out how Cant Be uses a riff almost like Laurie Andersons O Superman, and pairs it with a choir that sounds straight out of the Middle Ages. Gorgeous.

[USA] | Polyvinyl Record Co.

More digital thrashing from this chiptune quartet whose use of hacked Nintendo hardware to craft tunes has produced some truly delightful results. To prove that they are more than just a bunch of tech nerds with a love of neat noises, Lorem Ipsum (Arctic Anthem) derives its lyrics from Ciceros 1st-century BC debate about the difference between pleasure and goodness. Of course, rendered through Vocaloid treatment, youre listening to Latin sung by a possessed childs toy. Still, as one example of the groups album with words, so thats pretty good.

March 4 at the Biltmore Cabaret, 2755 Prince Edward St. Tickets and info: $24.00 at eventbrite.ca

Suddenly | Merge Records

Dan Snaith puts the past five years of his life down in a way he never has before on his latest release as Caribou. The opening song, Sister, is a haunting chant about making false promises and the need to break things to change them. Coming from the maths professor-cum-electronic musician, its a melancholy start to the dozen new tracks he selected out of a rumoured 900 to make this album. From the warped lounge piano jazz of Sunnys Theme to slinky sex groover Home, this is full of surprises. Obviously, there are some dance happy tracks too. Never Come Back will have backbones slipping.

All Or Nothing | Fat Cat

This U.K. trio really sounds like some long-lost release from the 1980s heyday of Gang of Four, Au Pairs and others was suddenly discovered, remastered and released. Songs such as Initiative, No Apologies or About You could all have been hits back then or today. Singer/guitarist Rachel Aggs has a way with laying melodic leads over top of bassist/vocalist Billy Easter and drummer/vocalist Andrew Milks mechanistic rhythms that just ripples with edginess. Its a sound that deserves reviving and revering.

March 7 at the Biltmore Cabaret, 2755 Prince Edward St. Tickets and info: $14.50 at eventbrite.ca

sderdeyn@postmedia.com

twitter.com/stuartderdeyn

Original post:
5 things to know about Miss Anthropocene by Grimes - Vancouver Sun

Posted in Transhumanist | Comments Off on 5 things to know about Miss Anthropocene by Grimes – Vancouver Sun

This AI Researcher Thinks We Have It All Wrong – Forbes

Posted: at 1:39 am

Dr. Luis Perez-Breva

Luis Perez-Breva is a Massachusetts Institute of Technology (MIT) professor and the faculty director of innovation teams at the MIT School or Engineering. He is also an entrepreneur and part of The Martin Trust Center for MIT Entrepreneurship. Luis works to see how we can use technology to make our lives better and also on how we can work to get new technology out into the world. On an episode of the AI Today podcast, Professor Perez-Breva managed to get us to think deeply into our understanding of both artificial intelligence and machine learning.

Are we too focused on data?

Anyone who has been following artificial intelligence and machine learning knows the vital centrality of data. Without data, we cant train machine learning models. And without machine learning models, we dont have a way for systems to learn from experience. Surely, data needs to be the center of our attention to make AI systems a reality.

However, Dr. Perez-Breva thinks that we are overly focusing on data and perhaps that extensive focus is causing goals for machine learning and AI to go astray. According to Luis, so much focus is put into obtaining data that we judge how good a machine learning system is by how much data was collected, how large the neural network is, and how much training data was used. When you collect a lot of data you are using that data to build systems that are primarily driven by statistics. Luis says that we latch onto statistics when we feed AI so much data, and that we ascribe to systems intelligence, when in reality, all we have done is created large probabilistic systems that by virtue of large data sets exhibit things we ascribe to intelligence. He says that when our systems arent learning as we want, the primary gut reaction is to give these AI system more data so that we dont have to think as much about the hard parts of generalization and intelligence.

Many would argue that there are some areas where you do need data to help teach AI. Computers are better able to learn image recognition and similar tasks by having more data. The more data, the better the networks, and the more accurate the results. On the podcast, Luis asked whether deep learning is great enough that this works or if we have a big enough data set that image recognition now works. Basically: is it the algorithm or just the sheer quantity of data that is making this work?

Rather, what Luis argues is that if we can find a better way to structure the system as a whole, then the AI system should be able to reason through problems, even with very limited data. Luis compares using machine learning in every application to the retail world. He talks about how physical stores are seeing the success of online stores and trying to copy on that success. One of the ways they are doing this is by using apps to help customers navigate stores. Luis mentioned that he visited a Target where he had to use his phone to navigate the store which was harder than being able to look at signs. Having a human to ask questions and talk to is both faster and also part of the traditional experience of being in a brick and mortar retail location. Luis says he would much rather have a human to interact with at one of these locations than a computer.

Is the problem deep learning?

He compares this to machine learning by saying that machine learning has a very narrow application. If you try to apply machine learning to every aspect of AI then you will end up with issues similar to the ones he experienced at the Target. Basically, looking at neural networks as a hammer and every AI problem as a nail. No one technology or solution works for every application. Perhaps deep learning only works because of vast quantities of data? Maybe theres another algorithm that can generalize better, apply knowledge learned in one domain to another better, and use smaller amounts of data to get much better quality insights.

People have tried recently to automate many of the jobs that people do. Throughout history, Luis says that technology has killed businesses when it tries to replace humans. Technology and businesses are successful when they expand on what humans can do. Attempting to replace humans is a difficult task and one that is going to lead companies down the road to failure. As humans, he points out, we crave human interaction. Even in the age where people are constantly on their technology people desire human interaction greatly.

Luis also makes a point that many people mistakenly confuse automation and AI. Automation is using a computer to carry out specific tasks, and it is not the creation of intelligence. This is something that many are mentioning on several occasions. Indeed, its the fear of automation and the fictional superintelligence that has many people worried about AI. Dr. Perez-Breva makes the point that many ascribe human characteristics to machines. But this should not be the case with AI systems.

Rather, he sees AI systems more akin to a new species with a different mode of intelligence than humans. His opinion is that researchers are very far from creating an AI that is similar to what you will find in books and movies. He blames movies for giving people the impression of robots (AI) killing people and being dangerous technologies. While there are good robots in movies, there are a few of them and they get pushed to the side by bad robots. He points out that we need to move away from this pushing images of bad robots. Our focus needs to be on how artificial intelligence can help humans grow. It would be beneficial if the movie-making industry could help with this. As such, AI should be thought of as a new intelligent species were trying to create, not something that is meant to replace us.

A positive AI future

Despite negative images and talk, Luis is sure that artificial intelligence is here to stay, at least for a while. So many companies have made large investments into AI that it would be difficult for them to just stop using them or to stop the development.

As a final question in the interview, Luis was asked where he sees the industry of artificial intelligence going. Prefacing his answer with the fact that based on the earlier discussion people are investing in machine learning and not true artificial intelligence, Luis said that he is happy in the investment that businesses are making in what they call AI. He believes that these investments will help the development of this technology to stay around for many years.

Once we can stop comparing humans to artificial intelligence, Luis believes that we will see great advancements in what AI can do. He believes that AI has the power to work alongside humans to unlock knowledge and tasks that we werent previously able to do. The point when this happens, he believes, is not that far away. We are getting closer to it every day.

Many of Luiss ideas are contrary to popular beliefs by many people who are interested in the world of artificial intelligence. At the same time, the ideas that he shares are presented in a very logical manner and are very thought-provoking. Time will tell if these ideas are in fact correct.

Go here to see the original:

This AI Researcher Thinks We Have It All Wrong - Forbes

Posted in Superintelligence | Comments Off on This AI Researcher Thinks We Have It All Wrong – Forbes

Melissa McCarthy Shares Advice With People: Life Is Short, Just Be Yourself – ETCanada.com

Posted: at 1:39 am

By Shakiel Mahjouri.15 hours ago

Melissa McCarthy has made a career out of being herself and she advises others to do the same.

McCarthy, 49, covers this weeks issue ofPeople. The Life of the Party actress celebrates her own unique qualities and discusses life with her daughters.

RELATED: Melissa McCarthy Plays Epic Prank On Unsuspecting Employees

How boring would it be if we were all the same? Were drawn to each other because of all our weird, unexplainable character quirks, the Little Big Shots host says. Life is short. Just be yourself!

McCarthy shares two daughters Vivian, 12, and Georgette, 10 with husband Ben Falcone. A big part of the actresss parenting has been to foster self-confidence.

My oldest has a really good head on her shoulders, but kids that age are always thinking, Does someone think I look silly? I tell them its all silly and were all idiots! she says. The second you embrace that and have realfriends, you realize thats the fun part.

RELATED: Melissa McCarthy Feels A Little Bit Sorry For Trolls

Who is the dumbest and the goofiest? McCarthy asks. Those are the friends youll have all your life.

McCarthy next stars in her husbands films Superintelligence opposite James Corden, and Thunder Force with Octavia Spencer.

Link:

Melissa McCarthy Shares Advice With People: Life Is Short, Just Be Yourself - ETCanada.com

Posted in Superintelligence | Comments Off on Melissa McCarthy Shares Advice With People: Life Is Short, Just Be Yourself – ETCanada.com

Hu+Machine: collaboration key to success for Australian mining – The West Australian

Posted: at 1:39 am

Driven by technology, the world is evolving at a rapid rate, with an increase in accessibility to all. Technology has become the fabric of our new reality, and the Australian mining industry is no different.

In Australia, businesses are accelerating the adoption of machines, robotics and artificial intelligence (Al), with 80 per cent of companies reporting AI is starting to make a presence in some form. Weve already seen great strides in mining, with autonomous transport in the form of trucks and trains, as well as self-healing equipment in plants and mining sites which proactively interact and work with technicians.

According to research by the World Economic Forum, 54 per cent of employees will need to be upskilled or reskilled by 2022, and by 2025, machines will be performing more than half of the work tasks, compared with the 29 per cent they do today.

AI gives humans superpowers in the form of amplification, interaction and embodiment. The way work is performed, where it takes place, who is responsible for tasks and how we reward employees is being reimagined.

By 2022, 58 per cent of tasks will be performed by humans and 42 per cent by machines and algorithms. Its predicted by 2021 there will be 7.5 billion active bots working in tandem with humans.

However, it is no longer a matter of Human vs Machines but rather Human + Machines.

Industries have successfully used technology and automation to improve efficiencies for decades. Thats nothing new. But the emergence of human and machine collaboration is.

Humachines (not to be mistaken with cyborgs), is a form of superintelligence which combines the smarts of big data and machine learning with a humans analytical, creative and intuitive mindset. Already, 49 per cent of business leaders believe its going to be the answer to achieving their strategic objectives and push the boundaries of how we work.

In fact, its expected AI enabled human and machine interfaces will replace one third of applications by 2024. Additionally, 49 per cent of business leaders believe the Human + Machine collaboration is important to achieve their strategic priorities. With humachine intelligence set to grow within the next five years, the Western Australian resources and mining industry has much to gain. At a time when the industry is going through unprecedented change, the opportunity to make a positive impact on climate sustainability, safety and the elimination of waste through the collaboration between human and machine is immense. Experts in human and technology collaboration, Accenture, calls this Triple Zero. This includes:

So, what does the future roadmap look like for the human workforce?

Its about redefining roles, exploring new business models and adapting to a more digitally savvy and fluid workforce, where we harness the power of machines to amplify human capabilities on the mine site. Machines are not just technology driven tools anymore, they are the next generation of employees.

Accenture Australia & New Zealand Natural Resources Lead Ann Burns said this wasnt a man versus machine scenario, its about how the two could co-exist and accelerate productivity in tandem.

Business leaders who look to understand and embrace the power of human and machine will find innovation will be rapid, and it will present new opportunities to make things better, easier, faster, smarter, safer and more sustainable.

For the mining industry, it will enable companies to tap into machine and human collaboration as the reality to their future success, unlocking new growth for WA and Australia.

Accentures Perth innovation hub works with global companies from all the resources and energy sectors to drive transformation and real innovation for them to grow at pace and scale. Visit the Perth Innovation Hub website to find out more.

Original post:

Hu+Machine: collaboration key to success for Australian mining - The West Australian

Posted in Superintelligence | Comments Off on Hu+Machine: collaboration key to success for Australian mining – The West Australian

Psoriasis: An update on topical therapies – Dermatology Times

Posted: at 1:38 am

New topical treatments for psoriasis increasingly prove that vehicles matter, says an expert who spoke at the South Beach Symposium. Additional noteworthy developments include new fixed combinations and new molecules under development.

RELATED:IL-23 inhibitors may offer psoriasis patients longer-lasting results

The polyaphron dispersion (PAD) vehicle platform (MC2 Biotek) includes 10 to 30 times less surfactants than other emulsions, which makes it less irritating, says Leon Kircik, M.D. He is clinical professor of dermatology, Icahn School of Medicine at Mount Sinai, New York; associate clinical professor of dermatology, Indiana University Medical Center; and Medical Director, Physicians Skin Care, PLLC, and Skin Sciences, PLLC, in Louisville, KY.

PAD technology also uses a robust lipid shell that allows high stability in aqueous environments.

"So now you have a less irritating, more durable vehicle," he adds.

In phase 3, the combination of calcipotriene and betamethasone diproprionate in the PAD vehicle (Enstilar foam, LEO Pharma) proved superior to a calcipotriene-betamethasone topical suspension ointment (Taclonex, LEO Pharma). The proportions of patients who were clear or nearly clear with at least a two-point improvement over baseline were 40% for the foam versus 22% for ointment.

Disclosures:

Dr. Kircik has served as an investigator, speaker, advisor or consultant for Amgen, Celgene, Clarify, Dermavant, LEO and MC2 Biotek.

References:

Leon Kircik, M.D. "Topical Therapies for Psoriasis," South Beach Symposium. February 8, 2020.

View original post here:
Psoriasis: An update on topical therapies - Dermatology Times

Posted in Psoriasis | Comments Off on Psoriasis: An update on topical therapies – Dermatology Times

Where Will Johnson & Johnson Be in 1 Year? – Motley Fool

Posted: at 1:38 am

Last year, shares of the big pharma company Johnson & Johnson(NYSE:JNJ) rose by 13%, a performance that trailed that of the pharmaceuticals industry, which was up by 24.7% as measured by the SPDR S&P Pharmaceuticals Index. The S&P 500 -- which was up by about 29% in 2019 -- also outpaced Johnson & Johnson last year.

There are several reasons why Johnson & Johnson did not perform as well as the broader market in 2019. First, some of its key products within its pharmaceuticals segment -- by far its largest segment by revenue -- have been recording declining sales. For instance, the company's rheumatoid arthritis drug Remicade reported $4.4 billion in sales for the full fiscal year 2019, down 17.8% year over year.Second, Johnson & Johnson is currently drowning in a sea of lawsuits. A California court recently ordered Johnson & Johnson to pay $344 million for "deceptively marketing" its pelvic mesh products, which are surgical implants aimed at treating pelvic organ prolapse.Johnson & Jonhson plans to appeal this decision, but there are more lawsuits the company has to worry about.

Amid all these troubles, investors might be inclined to avoid shares of the pharma giant altogether. However, a lot can happen in just one year, and despite its issues, Johnson & Johnson's trajectory within the next 12 months may not be that catastrophic. Here's why.

Image source: Getty Images.

While some of Johnson & Johnson's pharmaceutical products are losing steam, others are on the rise. The company's drug Stelara, which treats plaque psoriasis and psoriatic arthritis, recorded $6.4 billion in sales during fiscal year 2019, a 23.4% year-over-year increase. Tremfya, which is a treatment for severe plaque psoriasis, reported $1 billion in sales, up 85.9% compared with the previous fiscal year. Further, Johnson & Johnson's cancer drug Imbruvica recorded $3.4 billion in sales, up 30.4% year over year, and Darzalex -- which treats multiple myeloma-- recorded about $3 billion in sales, 48% higher than in fiscal year 2018.

In other words, Johnson & Johnson has enough products with sales on the rise -- and will likely continue delivering growing sales -- to keep revenue from its pharmaceuticals segment afloat. Some of the company's current products are also seeking additional indications.For instance, Imbruvica is currently in phase 3 testing for the treatment of mantle cell lymphoma, and Tremfya is in phase 3 testing for the treatment of pediatric psoriasis.

Also, Johnson & Johnson recently submitted a supplemental Biologics License Application to the U.S. Food and Drug Administration for Darzalex as a treatment for relapsed/refractory multiple myeloma (that is, multiple myeloma that does not respond to treatment or resurfaces after a period of remission). According to estimates, about 32,270 people will be diagnosed with relapsed/refractory multiple myeloma in 2020, and approximately 12,830 will die from it. Lastly, with the novel coronavirus outbreak worsening by the day, Johnson & Johnson is partnering with the U.S. Department of Health and Human Services to develop a vaccine for COVID-19, the deadly disease caused by the virus.

While Johnson & Johson boast a strong product lineup, the company has to contend with some competitors in these markets. For instance, AbbVie's (NYSE:ABBV) Humira is a treatment for plaque psoriasis. And although Humira is experiencing declining sales due to generic competition in Europe, it remains a blockbuster drug. Humira recorded $19.2 billion in sales in 2019.AbbVie's Skyrizi -- which also treats plaque psoriasis -- has been recording growing sales. Skyrizi was approved by the FDA for moderate to severe plaque psoriasis in April 2019, and the drug generated $355 million in sales last year.

Novartis (NYSE:NVS) is another pharma company with footprints in this market. The company's top-selling product Cosentyx, which treats moderate to severe plaque psoriasis -- generated $3.6 billion in sales last year.

In the market for multiple myeloma, Johnson & Johnson competes with Bristol-Myers Squibb (NYSE:BMY). Thanks to its acquisition of Celgene in a cash and stock transaction valued at $74 billion, Bristol-Myers acquired such products as Revlimid. Sales of Revlimid -- from the time of the closing of the acquisition on Nov. 20, to the end Bristol-Myers' third quarter, on Dec. 31 -- were $1.3 billion.Bristol-Myers should also submit ide-cel -- a potential treatment for relapsed/refractory multiple myeloma -- to the FDA sometime this year for approval.

Also,it isn't clear whether the company will benefit from its current efforts to develop a vaccine for COVID-19. While the epidemic continues to get worse -- with cases outside of China and in countries such as Italy and Iran growing --several companies are currently working on that project, and some of Johnson & Jonhson's peers could beat the company to the punch.

Even given these competitors, Johnson & Johnson's pipeline, as well as its current lineup should allow the company's sales to remain afloat.

One of Johnson & Johnson's biggest attractions is its dividend history. The company -- which ranks as one of the prestigious dividend aristocrats -- has more than 50 years of consecutive dividend increases under its belt,and Johnson & Johnson still affirms the importance of rewarding shareholders by way of dividend increases.

Chief Financial Officer Joseph J. Wolk said:

As investors in Johnson & Johnson know, delivering a competitive and increasing dividend is a capital allocation priority for us. In 2019, we returned almost $10 billion to investors, which is approximately 50% of our free cash flow, increasing the quarterly dividend by 5.6%.

The company's current dividend yield is 2.56%, and its payout ratio is 66.6%.Investors can count on Johnson & Johnson to keep increasing its quarterly dividend payout within the next year.

What should investors make of Johnson & Johnson's current legal troubles? On the one hand, the company has faced scores of lawsuits before. The pharma giant has always managed to come out of these relatively unscathed. The recent verdict mentioned above cost Johnson & Johnson $344 million. For context, this merely represents about 1.7% of the company's net sales during the fourth quarter.

On the other hand, these ongoing (and numerous lawsuits) represents a risk for Johnson & Jonhson. The company itself mentions risks, including "declining sales and reputational damage," that could ensue as a result of these lawsuits. Johnson & Jonhson continually monitors these legal troubles and the company records provisions for losses for those lawsuits for"which a loss is probable or reasonably possible."Investors should keep a close eye on the lawsuits that are currently plaguing Johnson & Johnson.

Johnson & Johnson didn't outperform the S&P 500 last year, and it is unlikely to do so this year. Also, there are other pharma giants that are likely to outperform the company over the next year. For instance, Bristol-Myers is still riding the wave from its Celgene acquisition and the company performed well during the fourth quarter. Further, Bristol-Myers currently provides better value. The company is trading at 8.44 times future earnings and its price to earnings growth (PEG) is 0.76. By contrast, Johnson & Johnson forward P/E is 14.9 while its PEG is 2.93. While I think both of these companies deserve consideration, I believe Bristol-Myers is a better pick given the 12 months time horizon.

Read this article:
Where Will Johnson & Johnson Be in 1 Year? - Motley Fool

Posted in Psoriasis | Comments Off on Where Will Johnson & Johnson Be in 1 Year? – Motley Fool

SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement – Proactive Investors UK

Posted: at 1:38 am

's () Stuart Ashman caught up with Proactive London's Andrew Scott following the news they've agreed a deal with Dutch firm Winclove Probiotics to develop a food supplement to combat psoriasis.

The pair plan to carry out a human study on mild to moderate sufferers of the skin condition, which will take between 12 and 18 months ahead of commercialisation and launch of the probiotic.

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company...

Go here to see the original:
SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement - Proactive Investors UK

Posted in Psoriasis | Comments Off on SkinBioTherapeutics teams up with Winclove Probiotics for psoriasis supplement – Proactive Investors UK

Fake News Alert: Video of Kazakhstan man shared as of Indian saint who took ‘samadhi’ 300 years ago – Pune Mirror

Posted: at 1:38 am

(This story was first published in the Times of India on February 21, 2020)

CLAIM

A loose translation of the Hindi text describing the video goes -- Siddha Yogi who took samadhi 300 years ago in Chennais Velayur Temple. The saint was found alive during the recent excavation works at the temple."

A reader sent the video along with this claim to Times Fact Check on our WhatsApp number 8527001433 to know if such an incident happened.

whatsapp query.

VERIFICATION AND METHODOLOGY

After breaking the video into different key frames using InVid Google Chrome extension, we ran reverse-image searches on them. This led us to a news report from Daily Mail UK, dated June 29, 2019.

Titled Bear man's identity is revealed: Doctor says emaciated 'living mummy' who appeared in shocking footage is really his patient suffering chronic psoriasis and was never mauled by beast, the report mentioned that the man in the video was actually a 41-year-old patient at Aktobe Medical Centre in Kazakhstan receiving treatment for severe psoriasis.

A senior medic from the hospital where hes admitted rubbished these claims and insisted that the 41-year-old man was never attacked by a wild beast and said he suffered from chronic psoriasis and other medical complications.

More:
Fake News Alert: Video of Kazakhstan man shared as of Indian saint who took 'samadhi' 300 years ago - Pune Mirror

Posted in Psoriasis | Comments Off on Fake News Alert: Video of Kazakhstan man shared as of Indian saint who took ‘samadhi’ 300 years ago – Pune Mirror